At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas
In Brief
A Phase 2 clinical trial evaluating Pasireotide Long Acting Release (LAR) for Neuroendocrine Tumors and Carcinoid Tumors. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied. The patient's physical state, changes in the size of the tumor, and laboratory findings taken while on-study will help us decide if Pasireotide LAR is safe and effective.
Study Details
Timeline
Interventions
Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.